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Abstract
Background: We conducted for the first time a systematic review, including a meta-analysis, of the incidence of
symptomatic rotavirus (RV) infections, because (1) it was shown to be an influential factor in estimating the cost-
effectiveness of RV vaccination, (2) multiple community-based studies assessed it prospectively, (3) previous studies
indicated, inconclusively, it might be similar around the world.
Methodology: Pubmed (which includes Medline) was searched for surveys assessing prospectively symptomatic (diarrheal)
episodes in a general population and situation, which also reported on the number of the episodes being tested RV+ and
on the persons and the time period observed. A bias assessment tool was developed and used according to Cochrane
guidelines by 4 researchers with different backgrounds. Heterogeneity was explored graphically and by comparing fits of
study-homogenous ‘fixed effects’ and -heterogeneous ‘random effects’ models. Data were synthesized using these models.
Sensitivity analysis for uncertainty regarding data abstraction, bias assessment and included studies was performed.
Principal Findings: Variability between the incidences obtained from 20 studies is unlikely to be due to study groups living
in different environments (tropical versus temperate climate, slums versus middle-class suburban populations), nor due to
the year the study was conducted (from 1967 to 2003). A random effects model was used to incorporate unexplained
heterogeneity and resulted in a global incidence estimate of 0.31 [0.19; 0.50] symptomatic RV infections per personyear of
observation for children below 2 years of age, and of 0.24 [0.17; 0.34] when excluding the extreme high value of 0.84
reported for Mayan Indians in Guatemala. Apart from the inclusion/exclusion of the latter study, results were robust.
Conclusions/Significance: Rather than assumptions based on an ad-hoc selection of one or two studies, these pooled
estimates (together with the measure for variability between populations) should be used as an input in future cost-
effectiveness analyses of RV vaccination.
Citation: Bilcke J, Van Damme P, Van Ranst M, Hens N, Aerts M, et al. (2009) Estimating the Incidence of Symptomatic Rotavirus Infections: A Systematic Review
and Meta-Analysis. PLoS ONE 4(6): e6060. doi:10.1371/journal.pone.0006060
Editor: Chris Mavergames, The Cochrane Collaboration, Germany
Received February 18, 2009; Accepted May 13, 2009; Published June 26, 2009
Copyright:  2009 Bilcke et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This study was made as part of ‘Simulation Models for Infectious Disease Processes (SIMID)’, a strategic basic research project funded by the institute
for the Promotion of Innovation by Science and Technology in Flanders (project number 060081). NH and MA acknowledge additional supportive funding from
the IAP research network nr P6/03 of the Belgian Government (Belgian Science Policy). The funders had no role in study design, data collection and analysis,
decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: joke.bilcke@ua.ac.be
Introduction
Meta-analyses of Randomized Controlled Trials (RCT’s) are
frequently undertaken as part of systematic reviews to estimate
clinical effect sizes. Effect size estimates based on meta-analyses
are even regarded as superior to estimates from a single RCT,
particularly when they serve as an input in Health Technology
Assessments(HTA’s) [1,2]. But clinical effect sizes are only one of
the many input variables needed for a HTA (others include
estimates on incidence of morbidity and mortality, costs and
utilities), and meta-analysis for estimating these other types of
variables have been used to a far lesser extent [1]. However, in
some cases (e.g. when data is available from different sources for
similar study groups, but not for the specific study group under
analysis), meta-analysis could be as strong a tool for good
estimation of these other types of variables, as it is for clinical
effect sizes.
This seems for instance the case for the estimation of the
incidence of symptomatic rotavirus (RV) infections, including
those that do not present to a physician or a hospital. Despite
common believe, several HTA studies showed this estimate to be
influential on the cost-effectiveness of RV vaccination [3–8].
However, many other studies considered only RV cases presenting
to physicians and hospitals [9–16], some of them justifying this by
claiming a lack of information on RV cases not presenting to a
physician or hospital. Nonetheless, a number of published studies
recorded prospectively the incidence of symptomatic RV infec-
tions. Moreover, De Zoysa and Feachem [17] already pointed out
that the incidence of symptomatic RV infections in a study group
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suggests that the incidence of RV diarrhoea may generally be
similar between developing and developed countries, and that
basic improvements in water supply, sanitation, hygiene, nutrition
and education do not necessarily reduce this incidence.
In short, because (1) the incidence of all symptomatic RV
infections can be an influential factor in estimating the cost-
effectiveness of RV vaccination, (2) multiple community-based
studies exist that assessed prospectively the incidence of symp-
tomatic RV infections, and (3) it would be important for global
public health policy to verify whether the incidence of symptom-
atic RV infections is similar around the world, we conducted a
systematic review, including a meta-analysis, of community-based
studies on the incidence of symptomatic RV infections. To our
knowledge this is the first meta-analysis on this subject. The main
aim of this meta-analysis is to produce reliable estimates of the
incidence of symptomatic RV infections, which can then be used
for HTA. Since this incidence was shown to be highly age-
dependent [17], age is taken into account.
Methods
The strategy used and the reporting hereafter is based on the
QUORUM [20] and MOOSE statement [21] and follows
Cochrane guidelines [22]. JB, who determined the strategy, is a
Biologist (BSc, MSc), Biostatistician (MSc), and current PhD
student. The strategy was implemented after conferring with PVD:
vaccinologist and infectious disease epidemiologist (PhD); MVR:
virologist and epidemiologist (PhD) and PB: infectious disease
modeller and economist (PhD). All these authors have worked and
published on RV before.
Searching
Pubmed, the main database for health sciences that fully includes
Medline, was searched using EndNote 9 (title, abstract and
keywords of each paper were searched). A first search of PubMed
to identify relevant papers for our meta-analysis was conducted on
September 6
th 2007 using search string ‘rotavirus’ AND ‘infection’
NOT ‘review’ NOT ‘letter’ NOT ‘clinical trial’. But as not all
relevant papers were detected through this search, a second, more
exhaustive search of PubMed was performed on January 16
th 2008
using the search terms ‘rotavirus AND diarrh*’ OR ‘rotavirus AND
symptom*’ OR ‘rotavirus AND gastroenteritis’ OR ‘rotavirus AND
gastro-enteritis’. This search was updated up to January 12
th 2009
to yield our final set of papers for review. All papers in foreign
languages (i.e. not familiar to any of the authors), but of possible
interest based on an English title and/or abstract were translated by
people ignorant of the purpose of our study. Papers published prior
to 1985 were excluded since relevant studies up to 1985 were taken
from the review on incidence of symptomatic RV infections
published in 1985 (de Zoysa & Feachem [17]).
Selection
All papers identified through the search were screened manually
for eligibility by JB, based on titles, abstracts and full text if
necessary. Only one person (JB) did the screening because of the
heavy workload involved. However, to assure high reliability of the
assessment of study eligibility, a detailed and complete list of
eligibility criteria was defined by multiple researchers (JB and PB,
advised by MVR and PVD), prior to scanning the references (as
recommended by Cochrane guidelines [22]):
– Original papers, i.e. excluding review papers, letters and
editorial comments.
– Descriptive studies (community surveys), i.e. not
comparative, hence excluding controlled trials and case-control
studies, because they often use a strictly controlled study design
(e.g. strict recruitment criteria), and because all participants
usually received some sort of intervention (placebo or treatment
of interest).
– Prospective, because RV testing is required to discern RV
from other infections as a cause of diarrhea, and such tests are
not standard practice. Therefore, RV cases should be recorded
prospectively, with RV testing included in the study protocol.
–I na‘general population, and general situation’,
because we want to estimate the incidence of all symptomatic
RV cases, and not restrict to cases for whom medical care is
sought, nor to cases occurring in a particular setting such as day
care centres, refugee camps and homes for the elderly. Reports
of outbreaks are also excluded, because they focus on a
particular period of time during which incidence is high.
– On humans, i.e. excluding studies of RV in animals.
– Reporting incidence of symptomatic laboratory-con-
firmed RV infections per person-year directly OR
reporting number/percentage of RV+ tests and
number/percentage of diarrheal/symptomatic infec-
tions (implying the number of symptomatic RV+
cases can be derived), and the person-time of
observation (or the number of persons under obser-
vation and the time period during which they were
observed). Studies assessing incidence of symptomatic RV
infection using serological assays and not stool tests are not
included, because it is very difficult to link symptoms with
blood tests indicating RV.
Validity assessment
In the absence of standard tools for validating studies that
measure non-comparative outcomes, a simple and transparent risk
of bias assessment tool was developed (for details see Text S1),
based on existing validation tools for studies on comparative
outcomes [22]. In a similar way as the ‘Cochrane collaboration’s
tool for assessing risk of bias’ [22], the tool consists of key sources
of bias (selection bias, confounders age and season, drop-outs and
detection bias) and is used to evaluate all studies that passed the
first two selection hurdles described above (database search and
eligibility criteria). Four assessors gave for each study a description
and judgement of each of these sources of bias (see Table S1). All
four assessors (JB, MVR, PB, PVD) had an adequate understand-
ing of the methods used for assessing the incidence of symptomatic
RV infections (see before), and MVR is an expert in laboratory
techniques used to identify rotaviruses. Although the use of
multiple assessors may limit bias, minimise errors and improve
reliability, it could give rise to disagreements [22]. Therefore, as
generally recommended [22], we adhered to the following
procedure:
1. Compare the individual assessments in group and try to come
to an agreement
2. If disagreement on a topic persists because of lack of knowledge
on this topic: gather the information to get agreement.
3. If impossible to come to an agreement: report different
opinions.
Based on a pilot study (for details see Text S1), it was decided
that assessors should not be blinded from the results section nor
author names, institutions and journal names because (1) the
Pooled Rotavirus Incidence
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on how potential confounders were dealt with, and (2) converting
the papers to a standardised anonymous format is labour intensive
at the arguably low benefit of excluding journal names for
assessors. We realise this could induce prejudice in interpretation
but we believe we minimized such prejudice by having four
independent assessors use a tool with specific questions. The
papers to evaluate were given to each of the four assessors in a
random order. Methodological papers from the reference lists
were provided to the assessors upon request. Although attempts to
assess risk of bias may be hampered by incomplete reporting, no
attempt was made to obtain missing information from authors.
Data abstraction
From each eligible paper, JB derived independently the
incidence of laboratory-confirmed symptomatic RV infections as
the number of such infections on the person-years of observation.
The abstraction method is made completely transparent by
reporting for each study in detail how the data were abstracted
(Table S2).
Study characteristics
All studies included are community surveys assessing prospec-
tively symptomatic (diarrheal) episodes in a general population and
situation (not restricted to e.g. day care centres), which also
reported on the number of the episodes being tested RV+, and on
the persons and the time period observed. Variation in study
characteristics and their possible impact on the study outcomes
was explored by plotting incidence per study according to a range
of study characteristics, such as person-years of observation, risk of
bias, Human Development Index (HDI, United Nations Devel-
opment Programme’s Human Development Report 2007/2008,
compiled on the basis of 2005 data), socioeconomic status of study
group (see further), and year in which the study was conducted (for
multi-year studies, the midpoint was taken). Note that the data are
too scarce to allow for a specific analysis with the aim of identifying
explanatory variables.
Quantitative data synthesis
Principal measure – Incidence of laboratory confirmed symptom-
atic RV infections, obtained as the number of such infections on
the personyears of observation. 95% credible intervals for the
incidence values reported in each study were obtained by taken
the 95% interval of a gamma distribution with parameters a, the
number of symptomatic RV+ episodes, and b, the inverse of the
personyears of observation. The gamma distribution conforms
with the gamma we assumed as a prior distribution in the models
(see below).
Statistical heterogeneity. Statistical heterogeneity was
explored graphically with a forest plot and by comparing the fit
of a fixed-effects (study-homogeneous) model with a random-
effects (study-heterogeneous) model [23]. The use of a random
effects model allows for variation between the studies and can be
used when the source of variation cannot be identified [22,23]. A
test for statistical heterogeneity (e.g. by calculating I
2) was not
performed, as we believe a pooled incidence estimate for
symptomatic RV infections makes sense, even in case of (some)
heterogeneity. This is because previous studies already indicated
incidence might be similar around the world as RV is so
contagious that basic improvements in water supply, sanitation,
hygiene, nutrition and education do not necessarily decrease
incidence. Note that incidence values taking into account possible
heterogeneity will also be estimated (see further).
Combining results. A pooled estimate for the incidence of
symptomatic RV infections was obtained by fitting the following
models to the data:
Study-homogeneous (‘fixed effects’) model: This model assumes
that the number of symptomatic RV infections, Y, as recorded in
each study can be sampled from a Poisson distribution with a
common mean (mti).
PY ~yi ðÞ ~




yi=the number of symptomatic RV infections for each study i
m=mean incidence rate (number of symptomatic RV infec-
tions/person-years of observation)
ti=person-years of observation for each study i
Study-heterogeneous (‘random effects’) model [24]: This model
allows the number of symptomatic RV infections recorded in each
study to deviate from the common mean mti by a factor mi, with mi
having a gamma distribution defined by parameter v (=shape
parameter and scale parameter, i.e. a gamma distribution with
common mean one and unknown variance). As mi works
multiplicative on the mean mti of the Poisson, a positive gamma
distribution with mean one is a logical choice to reflect the
heterogeneity of the studies compared to the global incidence.
With the above model, three types of incidences can be estimated:
N Global incidence m, a common incidence estimate not taking
into account heterogeneity between the studies.
N Incidence estimates for the study populations included in this
meta-analysis mim, taking into account the heterogeneity
between the studies.
N Incidence estimates for study populations not included in this
meta-analysis. This relates to the situation in which one wants
to estimate the incidence for a specific population (in HTA this
population will often be all children ,2 years of age of one
country) in the absence of empirical incidence estimates for this
specific population. If the study population is then not directly
comparable to any of the populations covered in our meta-
analysis, the uncertainty stemming from this incomparability
should be accounted for. This can be done by sampling from
the gamma distribution (Gamma(v,v)), conditional on the
posterior distribution for v to get an estimate for the deviation
from the global incidence mu, where mum represents the
incidence estimate. Note that the above procedure will
increase the 95% credible interval around the global incidence
estimate as more uncertainty is taken into account.
Models were fitted in Winbugs14, using uninformative gamma
priors for m and v (i.e. shape=scale parameter=1E-03), implying
results are not carried by the priors, but by the data. If possible,
age would be added as a covariate to the models (continuous or
ordinal, depending on the width of age intervals reported). In what
we termed hereafter ‘base case analysis’, the models were fitted on
the outcomes from the nine studies without high risk of bias.
Publication bias. Unlike for RCT’s and observational
studies on effects, for studies on incidence there is no reason to
not publish results (i.e. no publication bias) as it does not involve a
significance test for a certain treatment or intervention (and hence,
there is no possible bias to false-positive results).
Sensitivity analysis. To investigate whether the conclusions
rely on the inclusion/exclusion of any particular study, the meta-
Pooled Rotavirus Incidence
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study in turn. Data were also re-analysed where uncertainties
concerning the values extracted existed. Because there is little
consensus concerning the optimal way of dealing with study
validity in meta-analysis, the impact of excluding/including
outcomes of studies with (possible) high risk of bias was
investigated [22,23].
Results
Flow of included studies (Figure 1)
The literature search in Pubmed identified 5301 papers, 1016 of
which were published before 1985. Manual screening resulted in
37 papers fulfilling the predefined inclusion criteria. Another 16
papers were excluded due to the following reasons:
– Three papers [25–27] followed neonates for a very short
observation period (maximum 28 days).
– Twelve papers [28–39] did not provide sufficient information
on age of the study group.
– Two papers [40,41] reported on the same study, and are
further referred to as one study.
Incidence estimates were obtained from the remaining 21
studies, and for all these studies the risk of bias in the reported
outcomes was assessed. A separate reference list for the 5279
excluded studies, as recommended by the MOOSE statement
[21], can be found in the Reference List S1.
Study characteristics
The main characteristics of each of these 21 studies are
presented in Table 1. Papers were assigned to different categories
according to the socioeconomic status (SES) of the study group:
low (study group living in poor, crowded area), probably low
(studies performed in developing countries), not low (studies
performed in developed countries) or unclear (Table 1).
Data abstraction
From the 21 papers, the number of symptomatic RV infections
and person-years of observation were obtained for children under
2 years of age from all but one paper [42] (only data until age 1
available). Data on older children or adults were rare and often not
separately presented. Outcomes for yearly, 6-monthly and 3-
monthly age intervals could be obtained from 18, 15 and 3 papers
respectively.
Figure 1. Flow diagram of the studies reviewed.
doi:10.1371/journal.pone.0006060.g001
Pooled Rotavirus Incidence
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calculated directly using information provided by the study. For
instance, if the number of RV infections and/or person-years of
observation in the first and second year were reported separately,
they were summed to get the number of RV infections for the first
2 years. In case person-months or -days were given instead of
person-years of observation [18,41–53], the numbers were divided
by 12, respectively 365. For Espinoza et al [54], the person-years
of observation for age intervals 0–6 months and 6–12 months
could be obtained by dividing the person-years of observation in
the first year by two, because no drop-outs occurred during that
period. For Hasan et al [55], the number of symptomatic RV
infections was obtained by multiplying the number of diarrhea
cases by the proportion due to RV.
When number of symptomatic RV infections, and/or
person-years of observation was/were not reported, or could not
be calculated directly, we approximated it (for details see Table
S2).
The number of symptomatic RV infections and person-years of
observation did not always match: during the observation period,
stool samples were not always taken from all diarrhea episodes,
and/or not all stool samples were tested for RV. When no
adjustment is made for this, the incidence of symptomatic RV
infections is likely to be underestimated. Therefore the incidence
was adjusted by decreasing the person-years of observation by
multiplying it by the proportion of diarrheal episodes tested for
RV, when such information was given. For three of the papers
evaluated not to have high risk of bias in their reported outcomes
(and used in meta-analysis, see further) [41,48,56], the proportion
of diarrheal episodes tested for RV was uncertain, however
minimum and maximum proportions could be derived and/or
assumed (for details, see Table S2). In base case analysis, midpoints
Table 1. Background characteristics, incidence of symptomatic rotavirus infections per personyear of observation for children ,2
years and bias assessment of 21 prospective studies included in the meta-analysis.
ref country (location) inc
year of study
(midpoint) study group/situation ses bias
[18] Canada (Winnipeg, Manitoba) 0.24 1977 mothers in early postpartum period recruited at Health
Sciences Centre; not biased toward high socioeconomic class
NL P
[41] Mexico (San Pedro Martir, around the
southwestern outskirts of Mexico City)
0.38 1988 low income periurban area L N
[42,67] Nigeria (Ibadan)
1 NR children born at a General Hospital; lower socioeconomic class L H
[43] Chile (Poblacio ´n Carlos Condell slum, City of
Santiago)
0.19 1981 all families with children ,7years age living in slum L P
[44] Mexico (rural village appr 180 km southwest
of Mexico City)
0.33 1983 all children from the village U P
[45] Guinea-Bissau (suburban districts Bandim II
and Bele of Bissau)
0.24 1997 houses were randomly selected PL N
[46] Central African Republic (Bangui) 0.14 1985 children in maternity ward (living in neighbourhood of the ward) PL H
[47] Argentina (Avellaneda District, a suburb of
Buenos Aires)
0.13 1984 families recruited when seeing pediatrician at Primary Health
Care Center; low socioeconomic level, shantytowns, unstable
and overcrowded houses
LH
[48] Guatemala (Cauque ´) 0.84 1967 Mayan Indians; crowded L N
[49] Bangladesh (Mirpur, Dhaka) 0.25 2003 urban slum L P
[50] US (Northern Virginia) 0.22 1978 patients from a group pediatric practice; middle-class suburban
population
NL H
[51] Palestina (Gaza: Jebaliya) 0.08 1985 crowded, poor L P
[52] Costa Rica (Puriscal) 0.06 1983 children born in Hospital San Juan de Dios in San Jose ´ (97% of
babies from Puriscal are born here)
NL N
[53] China (suburb of Hong Kong) 0.06 NR low- to low-middle income families U H
[54] Nicaragua (Le ´on) 0.23 1992 children born in university hospital of whom mothers lived in
one of the 3 health areas in the city
NL N
[55] Bangladesh (10 villages in Mirzapur, rural
area appr 60 km from Dhaka)
0.21 1994 door-to-door census; crowded, poor L N
[56] Egypt (2 villages in the vicinity of a rural
district appr 40 km from Alexandria)
0.29 1995 house-to-house census U N
[57] Bangladesh (Enayet Nagar and Sepai Kandi) 0.41 1978 Matlab field research area L H
[58] Egypt (Epidemiology Study Center Field
research area near Bilbeis)
0.21 1982 8 villages were selected in the Epidemiology Study Center field
research area
UN
[59] Gambia (Bakau) 0.51 1982 representative 55% sample of locally born children PL H
[60] Brazil (peripheral area of Belem) 0.22 1984 poor housing, low socioeconomic level L N
Inc: incidence; SocioEconomic Status (ses): low (L: study group living in poor, crowded area), probably low (PL: studies performed in developing countries), not low (NL:
studies performed in developed countries) or unclear (U). NR: not reported, N: no high risk of bias, P: possible high risk of bias and H: high risk of bias in the reported
incidences.
1children were followed for the first year of life only.
doi:10.1371/journal.pone.0006060.t001
Pooled Rotavirus Incidence
PLoS ONE | www.plosone.org 5 June 2009 | Volume 4 | Issue 6 | e6060of those minimum-maximum ranges were used for adjustment.
When the proportion of diarrheal episodes tested for RV was given
for only one age interval, we assumed the same proportion for
other age intervals [42,45,54,55,57–59], for details see Table S2.
Adjustment (when necessary) was achieved for 15 of the 21 studies,
including all the studies without high risk of bias (see below).
Gurwithet al [18] provided outcomes per seasonso that we could
adjust for the oversampling in winter (for details see Table S2).
Assessment of risk of bias in the reported outcomes
The assessors came to agreement on the risk of bias for all studies.
Nine studies were evaluated to be without high risk of bias in the
reported incidenceofsymptomaticRVinfectionsand7studiestobe
with high risk of bias (the reasons are presented in Table S3).
Another 5 studies were evaluated as having a possible high risk of
bias in their reported outcomes. In 3 of them, information was
lacking so that validity assessment was not possible. The two other
studies presented the appropriate information, and based on this
they were regarded to be ‘borderline’, i.e. with risk of bias, but
unclear if this risk is high.
The nine ‘without high risk of bias’ studies all used ELISA for
RV testing, followed children at least for one complete year and
visited the child at least once a week, with the exception of one
study, in which the child was visited each time (s)he had diarrhea
[60].
Exploratory analysis
Incidence in children below 2 years of age varied between 0.06
and 0.84 symptomatic infections per person-year of observation
(Table 1, Figure 2). When only considering studies without high
risk of bias, the range stays the same, but the majority of studies
shows an incidence between 0.20 and 0.25 (Table 1, Figure 2).
Figure 2 indicates heterogeneity, but variation between the
studies seems not to be explained by differences in HDI,
socioeconomic status of the study group or the year when the
study was conducted, also not when only considering papers
without high risk of bias (Table 1 and Figure S1). Age-specific
incidences for yearly and 6-monthly intervals seem to vary even
more between the studies, i.e. some papers report the peak
incidence in the first year of life, whereas others found the
incidence to peak in the second year of life (Figure 3). A peak
incidence in the first year of life is due to a high incidence in the
first 6 months of life (e.g. [46,54]), or between 6 and 12 months of
age (e.g. [56,58,59]). Only 2 papers [48,52] with peak incidence in
the second year of life had information on incidence in 6 monthly
intervals, and report a high incidence between 12 and 18 months
of age. The six papers from which 6-monthly data until 2 years of
age could be derived [44–46,48,52,55], all demonstrate a decrease
in incidence for children aged 18–24 months.
Note that the variation in incidence between the studies without
high risk of bias is very unlikely to be explained by differences in
surveillance methods and/or RV tests, as these aspects were taken
into account in the bias assessment: all studies without high risk of
bias are considered to have used appropriate (i.e. unlikely leading
to over- or underestimation) methodology to assess symptomatic
RV episodes.
Quantitative data synthesis
As only few studies provided detailed information on incidence
of symptomatic RV infections by age, quantifying the variation by
age (by adding age as a covariate in the models) was not
considered feasible. Hence, all analyses are done on incidence
values for children below 2 years of age.
Base case analysis (9 studies without high risk of bias).
1. Global incidence estimate
The mean [95% credible interval] number of symptomatic RV
infections per person-year of observation is estimated at 0.26
[0.24; 0.29] (median 0.26) by the study-homogeneous ‘fixed
effects’ model and at 0.31 [0.19; 0.50] (median 0.30) by the study-
heterogeneous ‘random effects’ model. The DIC value of 160.0
(study-homogeneous model) compared to 67.4 (study-heteroge-
neous model) suggests the model taking into account heterogeneity
would best predict a replicate set of data of the same structure as
the data included in the meta-analysis.
2. Incidence estimates for the studies included in the meta-
analysis
The study-specific incidences estimated by the study-heteroge-
neous model and their 95% credible intervals are very close to the
reported ones (Table 2). The smallest (Simhon et al [52]) and
largest (Mata et al [48]) estimated values are most modified
towards the pooled incidence estimate.
3. Incidence estimate for study populations not included in the
meta-analysis
The 95% credible interval increases substantially due to the
extra source of uncertainty involved: 0.31 [0.05; 0.72].
Sensitivity analysis.
1. Meta-analysis on studies without high risk of bias: impact of
excluding any particular study
The exclusion of any single study from the meta-analysis does
not have a remarkable impact, with the exception of excluding the
Figure 2. Incidence of symptomatic RV infections in children
below age 2 for the 20 eligible studies. Forest plot showing
incidence (number of symptomatic RV infections per personyear of
observation; boxes) and 95% credible intervals (horizontal lines),
obtained from studies which were evaluated to be at respectively no
high risk of bias (‘no bias’), possible high risk of bias (‘possible bias’), and
high risk of bias (‘bias’). The size of each box is proportionate to the
person-years of observation from each study.
doi:10.1371/journal.pone.0006060.g002
Pooled Rotavirus Incidence
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pooled incidence estimate and its credible interval (Figure 4).
2. Meta-analysis on studies without high risk of bias: re-analysis
of data where uncertainties concerning values extracted exist.
From the papers of Mata et al [48], Naficy et al [56] and
Velazquez et al [41] it is unclear if all diarrheal episodes are tested
for RV (see Table S2). Impact of this uncertainty is investigated by
comparing the pooled incidence estimate when 100% testing of
diarrhea episodes is assumed for Mata et al [48] and Naficy et al
[56], and 100% testing of stool samples is assumed for Velazquez
et al [41], with the pooled incidence estimate when 85.5% and
80% testing of diarrhea episodes is assumed for Mata et al [48]
and Naficy et al [56], respectively and 80% testing of stool samples
is assumed for Velazquez et al [41].
The pooled incidence estimate varies then between 0.30 [0.19;
0.46] (100% testing assumed) and 0.33 [0.20; 0.56] (85.5/80%
testing assumed).
3. Impact of including studies with possible high risk of bias and
high risk of bias
Including the studies with possible high risk of bias renders a
slightly smaller pooled incidence estimate with a smaller credible
interval: 0.28 [0.20; 0.39]. The same occurs when including the
studies with high risk of bias: 0.27 [0.19; 0.35] (Figure 5).
4. Impact of the Mata et al paper [48]
When excluding the Mata et al paper [48], some heterogeneity
between the studies remains (DIC study-heterogeneous model is
60.7 compared to 82.4 for the study-homogeneous model). The
pooled incidence estimate lies then between 0.23 [0.17; 0.32]
(100% testing assumed for Naficy et al [56]and Velazquez et al
[41]) and 0.25 [0.17; 0.37] (80% testing assumed). When
excluding the Mata et al paper [48], the credible interval for
study populations not included in this meta-analysis becomes
smaller: 0.24 [0.09; 0.45]. Including the studies with possible high
risk of bias does not change the pooled ‘global’ incidence estimate,
but the credible interval decreases slightly: 0.24 [0.19; 0.30]. The
same occurs when including the studies with high risk of bias: 0.24
[0.18; 0.31] (Figure 5).
Discussion
We estimated the number of laboratory-confirmed symptomatic
RV infections per person-year of observation for children below 2
years of age, to be 0.31 [0.19; 0.50]. Excluding the high value
Figure 3. Incidence of symptomatic RV infections by age (in
years) obtained from different studies. Incidence is number of
symptomatic RV infections per personyear of observation. Black, grey
and white bars represent incidences for children in their first, second
and third year of life, respectively.
doi:10.1371/journal.pone.0006060.g003
Table 2. Reported and estimated (study-heterogeneous
meta-analysis model) incidence values of symptomatic RV
infections in children ,2 years.
REPORTED ESTIMATED
Study mean LL UL mean LL UL
Espinoza et al [54] 0.23 0.18 0.30 0.24 0.18 0.30
Fischer et al [45] 0.24 0.17 0.31 0.24 0.18 0.31
Hasan et al [55] 0.21 0.17 0.26 0.21 0.17 0.26
Linhares et al [60] 0.22 0.15 0.31 0.23 0.16 0.31
Mata et al [48] 0.84 0.66 1.06 0.79 0.61 0.99
Naficy et al [56] 0.29 0.21 0.38 0.29 0.21 0.38
Reves et al [58] 0.21 0.17 0.26 0.21 0.17 0.26
Simhon et al [52] 0.06 0.02 0.13 0.09 0.03 0.17
Velazquez et al [41] 0.38 0.31 0.47 0.38 0.31 0.46
Pooled estimate 0.31 0.19 0.50
LL: lower 95% credible limit, UL: upper 95% credible limit.
doi:10.1371/journal.pone.0006060.t002
Figure 4. Impact of excluding any particular study from meta-
analysis. Impact on the pooled estimate for the incidence of
symptomatic RV infections in children below 2 years of age. Squares
and horizontal lines represent means and 95% credible intervals of the
pooled estimates. Only studies without high risk of bias are considered.
doi:10.1371/journal.pone.0006060.g004
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Mata et al’s [48] estimate was based on a prospective follow-up
study in Mayan Indians in Guatemala, living in poor, crowded
areas. Other studies conducted in similar poor and crowded areas
reported much lower values for the incidence of symptomatic RV
infections (e.g. [41,45,55,60]). This could be due to the local or
ethnic pathogenicity of RV infections (e.g.: 39% versus 66% of RV
infections were symptomatic in Velazquez et al [41] and Mata et
al [48], respectively), or to a lower incidence of symptomatic and
asymptomatic RV infections combined (e.g. 0.6 versus 1.1 RV
infections per person-year for children ,2 years of age in Fischer
et al [45] and Mata et al [48], respectively). Also, the Mata et al
[48] study was performed at least 10 years earlier than the other
studies included, and RV tests were performed on faecal samples
that were frozen for 13 to 18 years. However, it remains unclear
whether these aspects explain the high incidence value.
The reported values of incidence of symptomatic RV infections
apply to children below two years of age, and are based on data
from different regions of the world (all continents, except for
Australia and Europe), with different climates (from tropical to
temperate), from populations with different socioeconomic status
(from the slums of the City of Santiago in Chile to a middle-class
suburban population in US), and at different times (1967–2003).
Although it has already been shown that the proportion of
gastroenteritis due to RV is seasonal, and that the extent of this
seasonality depends on region [61], the meta analysis indicates
region not to be an important determinant of the incidence.
Incidence seems also independent of socioeconomic status and year
of study, but one has to be aware of some limitations of the study:
Limitations
The number of studies involved in this review is restricted, and
additional information is needed to confirm results, especially with
respect to possible explanatory factors for observed differences in
incidences. For instance, only four studies in developed countries
and/or study groups not having a low socioeconomic status were
admissible for meta-analysis [18,50,52,54]. Therefore, it could be
of value to investigate the incidence of symptomatic RV infections
in the placebo groups of RCTs on RV vaccination, as many RCTs
were performed in developed countries (e.g. [62–65]). Other
factors possibly influencing the incidence of symptomatic RV
infection are the effect of breastfeeding and maternal antibodies,
virulence of the circulating strain, co-infections and co-morbidity,
etc.. Breastfeeding is believed to postpone symptomatic RV
infection to a later age, which could explain why in some papers
the incidence was found to peak in the second year of life, and not
in the first year of life as in the other studies. However, studies on
the protective effect of breastfeeding against RV infection have
yielded variable results [66].
Another limitation of this review is the nature of the outcome of
interest: there is no such thing as a ‘universally accepted’ method
to assess the number of symptomatic RV infections per person-
year of observation. Consequently, a large variety of methodol-
ogies are described by the papers, which could also (partially)
explain the variability in the reported outcomes between the
studies, i.e. the different papers did not necessarily measure the
same events. However, by conducting for each paper a very
exhaustive assessment of risk of bias in the reported outcome (with
respect to our outcome of interest), and by carefully extracting and
adjusting (if necessary) the outcomes of interest, we believe our
pooled estimates for the number of laboratory-confirmed symp-
tomatic RV infections per person-year of observation are reliable.
Furthermore, sensitivity analysis showed that these estimates were
robust for different selections of studies included in the meta-
analysis, with the exception of the study by Mata et al [48].
When one wants to estimate the incidence of symptomatic RV+
infections for a specific population for which no prospective studies
exist, and for which the resemblance with any of the populations
included in our meta-analysis is uncertain, one should use the
incidence estimates incorporating this extra source of uncertainty
(i.e. 0.31[0.05; 0.72] with and 0.24 [0.09; 0.45] without inclusion
of the Mata et al paper). The credible intervals reflect the different
sources of uncertainties involved. Therefore, despite being
relatively large these intervals are preferable to incidence estimates
derived from an ad-hoc selection of one or two prospective studies.
Clearly, once information is available on the incidence of
symptomatic RV+ infections for the specific population of interest,
incidence estimates and their credible intervals should be updated
using this new information.
Conclusion
In conclusion, given the currently available information, meta-
analysis was shown to be a useful tool in getting an estimate for the
incidence of symptomatic RV infections. Our study provides
relevant information for disease burden estimates of RV.
Furthermore the pooled (global) estimates, in combination with
an extra measure of uncertainty to account for variability between
studies (populations), should be used as an input in future CE
analyses of RV vaccination rather than an ad-hoc selection of one
or two of the studies we identified. As such, our meta-analysis fills
one of the most important gaps for CE analyses on this subject and
thus helps to reduce the uncertainty in the estimates they produce.
Supporting Information
Text S1 Detailed description of developing the tool for assessing
risk of bias.
Figure 5. Impact of including/excluding studies from meta-
analysis with possible high risk of bias, high risk of bias and
the Mata et al paper. Impact on the pooled estimate for incidence of
symptomatic RV infections for children below 2 years of age. Squares
and horizontal lines represent means and 95% credible intervals of the
pooled estimates. Ho=study-homogeneous model, He=study-hetero-
geneous model, NR=only studies with no high risk of bias included,
NPR=studies with no or possible high risk of bias included,
ALL=studies with no, possible or high risk of bias included, n=number
of studies included in meta-analysis.
doi:10.1371/journal.pone.0006060.g005
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Figure S1 Incidence of symptomatic RV infections by study
characteristics. Incidence of symptomatic RV infections per
personyear of observation in children below age 2 by Human
Development Index (HDI) of the country where each study was
conducted, socioeconomic status of the study group (0=low;
1=probably low; 2=not low; 4=unclear), and year in which the
study was conducted (for multi-year studies, midpoint was taken).
Black, grey and white circles represent incidences that were
evaluated to be at respectively no high risk of bias, possible high
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proportionate to the personyears of observation.
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